BioMarin Pharmaceutical (BMRN) : 14 analysts are covering BioMarin Pharmaceutical (BMRN) and their average rating on the stock is 1.29, which is read as a Strong Buy. 11 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. BioMarin Pharmaceutical (BMRN) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
BioMarin Pharmaceutical (BMRN) : Currently there are 14 street experts covering BioMarin Pharmaceutical (BMRN) stock. The most bullish and bearish price target for the stock is $150 and $99 respectively for the short term. The average price target of all the analysts comes to $118.64. The estimated standard deviation from the target is $12.04.
Shares of BioMarin Pharmaceutical Inc. rose by 8.38% in the last five trading days and 7.16% for the last 4 weeks. BioMarin Pharmaceutical Inc. is up 13.05% in the last 3-month period. Year-to-Date the stock performance stands at -5.09%. BioMarin Pharmaceutical (NASDAQ:BMRN): stock turned positive on Tuesday. Though the stock opened at $99.11, the bulls momentum made the stock top out at $99.95 level for the day. The stock recorded a low of $97.44 and closed the trading day at $99.43, in the green by 1.28%. The total traded volume for the day was 1,695,976. The stock had closed at $98.17 in the previous days trading.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).